$-0.43 EPS Expected for Intellia Therapeutics Inc. (NTLA)
February 15, 2018 – By Henry Gaston
Analysts expect Intellia Therapeutics Inc. (NASDAQ:NTLA) to report $-0.43 EPS on March, 13.They anticipate $0.12 EPS change or 38.71 % from last quarter’s $-0.31 EPS. After having $-0.44 EPS previously, Intellia Therapeutics Inc.’s analysts see -2.27 % EPS growth. The stock decreased 2.17% or $0.56 during the last trading session, reaching $25.24. About 277,058 shares traded. Intellia Therapeutics Inc. (NASDAQ:NTLA) has declined 46.16% since February 15, 2017 and is downtrending. It has underperformed by 62.86% the S&P500.
Intellia Therapeutics Inc. (NASDAQ:NTLA) Ratings Coverage
Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. Jefferies initiated the shares of NTLA in report on Tuesday, May 31 with “Hold” rating. Jefferies upgraded the shares of NTLA in report on Friday, August 5 to “Buy” rating. Leerink Swann upgraded the stock to “Outperform” rating in Friday, August 5 report. The firm earned “Outperform” rating on Tuesday, May 31 by Wedbush. On Tuesday, May 31 the stock rating was initiated by Credit Suisse with “Outperform”.
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.07 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.
More news for Intellia Therapeutics Inc. (NASDAQ:NTLA) were recently published by: Globenewswire.com, which released: “Intellia Therapeutics to Present at February Healthcare Investor Conferences” on January 31, 2018. Fool.com‘s article titled: “Here’s What Pushed Intellia Therapeutics Inc. Up 33.7% in January” and published on February 08, 2018 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.